MELBOURNE, Australia--(BUSINESS WIRE)--Dec. 1, 2005--Norwood Abbey Ltd (ASX: NAL) advises that key patents relating to Norwood Immunology’s (NIM) technology have been granted in Singapore and New Zealand. The grant of these patents strengthens NIM’s Intellectual Property position in its key areas of cancer and infectious diseases. NIM is involved in clinical studies into enhancing the immune system of cancer patients and improving their response to vaccines.
